4-(2-二乙基氨基乙基)哌啶 | 64168-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(2-二乙基氨基乙基)哌啶
• 英文名称: diethyl-(2-[4]piperidyl-ethyl)-amine
• 英文别名: Diaethyl-(2-[4]piperidyl-aethyl)-amin；4-(2-diethylamino-ethyl)-piperidine；N,N-diethyl-4-piperidineethanamine；4-(2-Diethylaminoethyl)piperidine；N,N-diethyl-2-piperidin-4-ylethanamine
• CAS: 64168-10-1
• 化学式: C₁₁H₂₄N₂
• 分子量: 184.325
• InChiKey: LKFIRLHXHMMYGO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  CORROSIVE
• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  4-(2-二乙基氨基乙基)哌啶 在 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 72.0h， 生成
  参考文献：
  名称：

  Molecular modulation of muscarinic antagonists. Synthesis and affinity profile of 2,2-diphenyl-2-ethylthio-acetic acid esters designed to probe the binding site cavity

  摘要：

  The synthesis and preliminary pharmacological profile of a new series of muscarinic antagonists, derived from previously studied 2,2-diphenyl-2-ethylthio-acetic acid esters, are reported. The parent molecules were decorated with linkers of different length, carrying an amino group to catch a putative anionic function outside the recognition site of the receptor. It was hoped that the interception of this function would give molecules with higher potency and selectivity. The attempt has not been successful, but a new series of compounds with a peculiar pharmacological profile has been identified.

  DOI：

  10.1016/j.farmac.2004.08.003
• 作为产物：
  描述：

  4-(2-二乙基氨基乙基)-吡啶 在 platinum(IV) oxide 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 以89%的产率得到4-(2-二乙基氨基乙基)哌啶
  参考文献：
  名称：

  某些5-[[[[（（二烷基氨基）烷基] -1-哌啶基]乙酰基] -10,11-二氢-5H-苯并[b，e] [1,4]二氮杂pin-11-酮的合成及构效关系作为M2选择性抗毒蕈碱药。

  摘要：

  制备了一系列5-[[[[（二烷基氨基）烷基] -1-哌啶基]乙酰基] -10,11-二氢-5H-二苯并[b，e] [1,4]-二氮杂-11-酮M2选择性配体。评价化合物对毒蕈碱胆碱能受体的亲和力和选择性。研究的最好的M2选择性抗毒蕈碱剂是5-[[4- [4-二乙基氨基）丁基] -1-哌啶基]乙酰基] -10,11-二氢-5H-二苯并[b，e] [1,4]二氮杂ze -11-，在M2受体上的效力比以前已知的化合物（例如11-[[4- [4-（二乙基氨基）丁基] -1-哌啶基]乙酰基] -5,11-二氢-6H）强约10倍-吡啶基[2，3-b] [1，4]苯并二氮杂-1-酮（AQ-RA 741）。

  DOI：

  10.1021/jm00053a021

文献信息

• Topical formulations for treating allergic diseases
  申请人：Hellberg R. Mark

  公开号：US20050288283A1

  公开（公告）日：2005-12-29

  Methods for topically treating allergic diseases of the eye, ear or nose using tricyclic compounds are disclosed.

  揭示了使用三环化合物治疗眼、耳或鼻过敏疾病的方法。
• Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain
  申请人：Barth Martine

  公开号：US20060178360A1

  公开（公告）日：2006-08-10

  The present invention concerns novel benzenesulphonamide compounds, defined by formula I and the description, their method of preparation and their use in therapy.

  本发明涉及新型苯磺酰胺化合物，由公式I和描述所定义，其制备方法及在治疗中的用途。
• Condensed diazepinones, processes for preparing them and pharmaceutical
  申请人：Dr. Karl Thomae GmbH

  公开号：US04931436A1

  公开（公告）日：1990-06-05

  New condensed diazepinones of general formula I are described ##STR1## wherein B represents one of the divalent groups ##STR2## and X.sup.1, X.sup.2, A, R.sup.1 to R.sup.10 and Z are defined as in the specification.

  描述了一种一般式I的新型缩合二氮杂环酮，其中B代表二价基团之一，而X.sup.1、X.sup.2、A、R.sup.1至R.sup.10和Z的定义如规范中所述。
• Synthesis of New Cardioselective M2 Muscarinic Receptor Antagonists.
  作者：Giacomina R. MANDELLI、Stefano MAIORANA、Patrizia TERNI、Giuseppina LAMPERTI、Maria Luisa COLIBRETTI、Bruno P. IMBIMBO

  DOI：10.1248/cpb.48.1611

  日期：——

  A series of 5H-dibenz[b, f]azepine derivatives was prepared and evaluated for binding affinities to muscarinic receptors in vitro. Among them, compound 8 showed a high affinity for human recombinant M2 receptors (Ki=2.6 nM), a low affinity for M4 receptors (39-fold less than for M2 receptors) and a very low affinity for M1 and M3 receptors (119- and 112-fold less than for M2 receptors, respectively). The high M2 selectivity of 8 may be attributed to the olefinic bond of the azepine ring. Functional experiments showed 8 to be a competitive antagonist with high affinity to the cardiac (pA2=7.1) and low affinity to the intestinal muscarinic receptors (IC50=0.54 μM). In vivo experiments confirmed the in vitro M2 selectivity of 8. Acetylcholine-induced bradycardia was dose-dependently antagonized in rats after both intravenous and intraduodenal administration of 8. In rats, cholinergic functions mediated by M1 or M3 receptors (salivary secretion, pupil diameter, gastric emptying, intestinal transit time) were not affected by the oral administration of 8 even at doses as high as 30 times the antibradycardic effective dose. Furthermore, 8 had no analgesic activity in mice, indicating poor central nervous system penetration. In dogs, nocturnal bradycardia was dose-dependently inhibited by the oral route with a duration of action of about 24 h. Compound 8 appears to be a promising cardioselective antimuscarinic agent for the treatment of dysfunctions of the cardiac conduction system such as sinus or nodal bradycardia ("sick-sinus syndrome") and atrioventricular block.

  一系列5H-二苯[b, f]氮杂环戊烯衍生物被合成并评估其对体外毒蕈碱受体的结合亲和力。在这些化合物中，化合物8对人重组M2受体表现出高亲和力（Ki=2.6 nM），对M4受体的亲和力较低（比M2受体低39倍），对M1和M3受体的亲和力非常低（分别比M2受体低119倍和112倍）。化合物8的高M2选择性可能归因于氮杂环上的烯键。功能实验表明，8是一个竞争性拮抗剂，对心脏的亲和力较高（pA2=7.1），而对肠道毒蕈碱受体的亲和力较低（IC50=0.54 μM）。体内实验确认了8的体外M2选择性。经过静脉注射和十二指肠内给药后，乙酰胆碱诱导的心动过缓在大鼠中呈剂量依赖性被拮抗。在大鼠中，介导M1或M3受体的胆碱能功能（唾液分泌、瞳孔直径、胃排空、肠道转运时间）在口服给药8的情况下未受到影响，即使在高达抗心动过缓有效剂量30倍的剂量下。此外，8在小鼠中没有镇痛活性，表明其对中枢神经系统的穿透性差。在犬中，口服给药后夜间心动过缓呈剂量依赖性抑制，作用持续约24小时。化合物8似乎是一种有前途的心脏选择性抗毒蕈碱药物，可用于治疗心脏传导系统的功能障碍，如窦性或结性心动过缓（“病态窦综合征”）和房室传导阻滞。
• Muscarinic receptor antagonists
  申请人：Aggen James

  公开号：US20090306134A1

  公开（公告）日：2009-12-10

  Disclosed are multibinding compounds which are muscarinic receptor antagonists. The multibinding compounds of this invention containing from 2 to 10 ligands covalently attached to one or more linkers. Each ligand is, independently of each other, a muscarinic receptor antagonist or an allosteric modulator provided that at least one of said ligand is a muscarinic receptor antagonist. The multibinding compounds of this invention are useful in the treatment and prevention of diseases such as chronic obstructive pulmonary disease, chronic bronchitis, irritable bowel syndrome, urinary incontinence, and the like.

  本发明涉及一种多结合化合物，其为肌动蛋白受体拮抗剂。该发明的多结合化合物包含2至10个配体共价连接到一个或多个连接体上。每个配体是独立的，可以是肌动蛋白受体拮抗剂或变构调节剂，但至少其中一个配体是肌动蛋白受体拮抗剂。本发明的多结合化合物在治疗和预防慢性阻塞性肺疾病、慢性支气管炎、肠易激综合征、尿失禁等疾病方面具有用途。